Following Wednesday's market close, Steven Mento, president, CEO and co-founder of Conatus Pharmaceuticals Inc., carefully walked analysts and investors through the rationale, design and opportunities to learn from the phase IIb POLT-HCV-SVR trial of individuals with post-transplant fibrosis and cirrhosis – a group, he emphasized on the conference call, that's not been studied previously.